The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function.
|Number of pages||3|
|Journal||Eksperimental'naya i Klinicheskaya Farmakologiya|
|Publication status||Published - 2003|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)